<DOC>
	<DOCNO>NCT01430429</DOCNO>
	<brief_summary>The purpose study assess safety efficacy multiple dose NI-0801 primary biliary cirrhosis patient inadequate response ursodeoxycholic acid .</brief_summary>
	<brief_title>Primary Biliary Cirrhosis : Investigating A New Treatment Option Using NI-0801 , Anti-CXCL10 Monoclonal Antibody</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Proven primary biliary cirrhosis ( PBC ) , demonstrate presence least 2 follow 3 diagnostic factor ( History increase alkaline phosphatase level least 6 month ; positive serum AMA titer ; Liver biopsy consistent PBC ) Elevated liver enzyme level screen Have give write informed consent Screening bilirubin &gt; 2.9 mg/dL ( 50 Î¼mol/L ) Screening creatinine clearance &lt; 80 ml/min History presence hepatic decompensation ( e.g. , esophageal variceal bleeding , hepatic encephalopathy , ascites ) Positive serology result Human Immunodeficiency Virus ( HIV ) , Hepatitis B C Known previous diagnosis malignancy Presence active infection Previous history active TB within 12 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>